Develops cellular therapies for cancer using encapsulated live human cells.
Jul 2026Revenue $0.00/yrExpenses $7.01M/yr
No trendCash runway ≈ 4.5 years from Jul 2026
Figures by year
When will PharmaCyte Biotech be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jul 2026, revenue was $0.00 and expenses $7.01M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Apr 2026 | $0.00 | $6.85M | −$6.85M |
| Apr 2025 | $0.00 | $4.38M | −$4.38M |
| Apr 2024 | $0.00 | $8.52M | −$8.52M |
| Apr 2023 | $0.00 | $6.46M | −$6.46M |
| Apr 2022 | $0.00 | $4.39M | −$4.39M |
| Apr 2021 | $0.00 | $3.62M | −$3.62M |
| Apr 2020 | $0.00 | $3.83M | −$3.83M |
| Apr 2019 | $0.00 | $4.10M | −$4.10M |
| Apr 2018 | $0.00 | $6.98M | −$6.98M |
| Apr 2017 | $0.00 | $4.44M | −$4.44M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.